Physician profile
Codie Vassar
NPI 1538690995
$1,763.23
in general payments reported to CMS, 2019-2025
17 companies · $478 in 2025
The $478 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $107 · 2022: $252 · 2023: $81.46 · 2024: $845 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $339.12 | 2022-2025 | Vraylar |
| Axsome Therapeutics, INC. | $285.34 | 2024-2025 | Auvelity |
| Alkermes, INC. | $181.36 | 2021-2024 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $162.65 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.69 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $135.51 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $110.52 | 2022-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $90.05 | 2024-2025 | Rexulti |
| Tris Pharma INC | $68.19 | 2024-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $67.61 | 2024-2025 | Invega Sustenna, Spravato |
| Neos Therapeutics, LP | $39.70 | 2024 | Adzenys Xr-Odt |
| Indivior INC. | $34.62 | 2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $23.23 | 2024 | Cobenfy |
| Lundbeck LLC | $22.80 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $21.27 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $17.77 | 2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $14.80 | 2024 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Codie Vassar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.